A team led by the Garvan Institute of Medical Research has revealed a new approach for classifying breast cancer subtypes based on their cell profile, which could help personalize treatments for patients.
By analyzing breast cancer biopsies from patients at Sydney hospitals, the researchers revealed more than 50 distinct cancer, immune and connective cell types and states, which could assign breast cancers to one of nine cancer ‘ecotypes’, each of which was associated with a different cancer prognosis.
“Our research has uncovered a cellular model for how we group cancers, which may be a powerful method to help personalize breast cancer treatments,” says Associate Professor Alex Swarbrick, Head of the Tumour Progression Lab at Garvan and senior author of the paper published in Nature Genetics.
The team is now aiming to develop a clinical test that will ‘ecotype’ cancers to determine which treatment is best suited to which patient.
“Tumors are not made up of a single cell type, but rather a complex mix of cancer, immune and connective tissue cells, that all play a role in tumor progression and prognosis. Our new ecotyping approach for stratifying breast cancers based on all the individual cells they contain may inform therapy strategies that improve outcomes for patients.”
Breast cancer in unprecedented detail
Breast cancers are currently classified into three clinical subtypes (luminal, HER2+ and triple negative), based on specific receptors they do or do not produce. While these subtypes are used to estimate prognosis and guide treatments, not all breast cancers respond to this strategy, with the disease still claiming 3000 lives in Australia alone each year.
“Current methods for classifying breast cancers only provide a limited picture of the complex biology contained in the tumors. Classifying breast cancers based on their entire composition of cells can provide a new and comprehensive view of a cancer. We wanted to develop an accessible framework for this,” says Sunny Wu, co-first author of the study.
Using cellular and spatial genomics technologies, which analyze individual cells and map their location within a tissue sample, the researchers assessed breast cancer biopsies from 26 patients at Sydney hospitals, including from St Vincent’s Hospital Sydney and The Chris O’Brien Lifehouse. These samples were analyzed in the Garvan-Weizmann Centre for Cellular Genomics.
“We looked at the complete cell profile of each breast cancer sample and revealed more than 50 different cell types or cell states that were present. We then analyzed publicly available data from thousands of breast cancer patients and by assigning the new cell types and states discovered nine recurring patterns, which we define as ‘ecotypes’,” says Ghamdan Al-Eryani, co-first author of the study.
“Each of these ecotypes directly corresponded with a different clinical outcome in patients, which is why we think they may help reveal which treatment a tumor will best respond to,” adds co-first author Dr. Daniel Roden.
Developing a new diagnostic approach
The Garvan team will next explore how their ecotyping method could be introduced in a clinical diagnostics pipeline, as a predictive test for personalized treatment.
“One thing that is characteristic about each ecotype is their profile of immune cells. We expect that this would relate to a cancer’s response to immunotherapy, and identify patients that could benefit from this treatment,” says Associate Professor Swarbrick.
“For instance, we found one breast cancer ecotype that uniquely has a high number of infiltrating lymphocytes, which are the target of current immunotherapies, and low levels of cells that we know to suppress lymphocytes. We would predict that those patients would respond well to immunotherapy, which is highly effective in some cancers, such as melanoma or lung cancer, but has a response of less than 10% in breast cancer patients.”
“This study has shown us how crucial the complete cellular profile of tumors is to advancing breast cancer research aimed at personalized treatments,” he adds.
Source: Read Full Article